Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 7, 2011Clinical Cancer ResearchOpen Access

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo

View Full Paper
Ask AI
Bookmark
Share

Authors

TNTri NguyenHarvard UniversityYDYun DaiUniversity of MiamiEAElisa Attkisson

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nguyen et al. (2011) studied this question.

synapsesocial.com/papers/69d74ef458d71cbec648f71dhttps://doi.org/10.1158/1078-0432.ccr-11-0234
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Translation of the Philadelphia chromosome into therapy for CML2008 · 665 citations
  2. 2The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species2001 · 490 citations
  3. 3MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/8252007 · 56 citations
  4. 4KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation2009 · 132 citations
  5. 5Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia2007 · 650 citations